Privacy    
 
  Citi Research Disclosures


ABCDEFGHIJKLMNOPQRSTUVWXYZ#




Disclosures Home
Conflicts Management Policy
SEBI Investor Charter & Complaint Information
SEBI Prescribed Client Terms & Conditions
Staff Conflicts
Terms of Use

 
Valuation & Risks ( ARCLK.IS ) Disclosure / Price Chart(s) / Valuation & Risk
Fundamental Equity Research
Our target price for Arcelik is TL170 and is based on target multiple valuation: we apply a 5x EV/EBITDA multiple (in line with 5y average) to our 2026E estimates.

We assign a High Risk rating which we think is appropriate considering Arcelik's elevated share price volatility and high leverage. Downside risks to our target price and investment thesis include: 
(1) Macro volatility – a slower rate cut path could lead to a weaker recovery in discretionary demand.
(2) Deterioration in consumer sentiment could lead to a drop in volumes resulting in lower capacity utilization.
(3) Challenging M&A integration and weaker-than-expected European margin recovery. 
(4) Higher competition and pricing pressure primarily from Chinese producers. 
(5) Raw cost materials price increases leading to GM pressure. 
Upside risks to our target price and investment thesis include:
(1) Stronger-than-expected progress on EU assets turnaround.
(2) Stronger pricing that can offset cost pressure, leading to higher margins. 
(3) Cancellation of acquired treasury shares (~10%).

 

 

citiPrivacy
www.citigroup.com Terms, conditions, caveats, and small print
Copyright © 2025 Citi